Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet Respiratory Medicine
The post Covid-19: Inhaled Nebulized Interferon Beta-1a shows potential for hospitalized patients in preliminary trial appeared first on Links Medicus.